Life Sciences Archive » September, 2021

Life Sciences - September, 2021

317 articles

• 'What's The Evidence?' Calif. Judge Asks After Big Opioid Trial
• 11th Circ. Hands Catalyst Win In 'Orphan Drug' Case
• Allergan Must Face Generic Drug Price-Fixing Claims
• Sun Pharma's Eye Pain Patent Invalidated
• Fed. Circ. Forecast: Verisk Targets EagleView's $375M Win
• Cherokee Want Pharmacies In State Court After Opioid Deal
• Gunderson-Led Theseus Pharma To Launch $125M IPO
• Texas Court Puts Gilead Medicaid Fraud Suit On Ice
• MacroGenics Escapes Investor Stock Drop Suit
• Vaxart Buried Investors In 'Avalanche Of B.S.,' Judge Says
• J&J Sunscreen Carcinogen Suits Doubtful For MDL In NJ
• Westco Chemicals 401(k) Settlement Rejected Over Fairness
• Mass., West Pa. Cited As Viable Homes For Philips CPAP MDL
• Deals Rumor Mill: Willis Towers Watson, Huntsman, Fanatics
• Covington, Ropes Lead Merck's $11.5B Acceleron Pharma Buy
• Device Co. Can Search Tim Cook's Emails In Apple Patent Suit
• Celgene Ended Theranos Deal Early Over Bad Data, Jury Told
• 7 Key Details As Pharmacy Giants Head To 1st Opioid Trial
• Bills To Cut Drug Prices, Fight Counterfeits Sent To Full House
• Split 9th Circ. Revives Calif. Chemical Water Case
• Judge Orders Mallinckrodt Trial On Acthar Antitrust Claims
• New Calif. Law Expands Access To Medical Pot In Hospitals
• Boeing Case Highlights Risk For Health, Life Sciences Boards
• Vein Filter Victim Calls On Pa. Justices For Tort Law Shake-Up
• Del. Judge Invalidates Stanford Kidney Test Patents
• Court Rejects Challenge To Ill. Cannabis Licensing Scheme
• What 9th Circ. Privilege Test Means For Dual-Purpose Advice
• Sidley Austin Snags 3 Former FDA Attys From Hogan Lovells
• Ex-Insys Sales Rep Admits Guilt On Day 4 Of Kickbacks Trial
• Truck Co. Navistar Must Face Suit Over EPA Standards Claims
• AstraZeneca Buys Rare Disease Drugmaker For Up To $500M
• Holmes Texts Show Investor Cash Poured In As Lab Struggled
• Public Health Groups Urge FDA To Speed Up E-Cig Reviews
• Herbalife Trims But Can't Escape $1B Fraud Suit
• DC Circ. Hears DEA Should Not Oversee Hemp Manufacturing
• FTC Settles Antitrust Case Against Alabama Dental Board
• In COVID Fight, Nonprofits Ask White House For IP Waivers
• 'Overheated': How A Chinese-Spy Hunt At DOJ Went Too Far
• SEC Says Cannabis Pill Maker Ran $2M Securities Fraud
• J&J Wins Multiplaintiff Mo. Talc Trial After High Court Setback
• Drug Cos. Say DA's Opioid Settlement Objections Are Unripe
• Male Ex-Worker Drops Pay Bias Suit Against Emory U.
• Lifting The Veil On The Supreme Court's Shadow Docket
• Endo Agrees To $7.5M Deal With La. AG Over Opioid Claims
• College Of NJ Students Aim To Block COVID Vaccine Mandate
• Cherokee Nation Inks $75M Opioid Deal With Distributors
• NY Bankruptcy Judge Who Oversaw Purdue Ch. 11 Will Retire
• 3 Patent Eligibility Reform Ideas Add Clarity But Bring Risks
• Leahy's Bill Seeks To 'Course Correct' From Iancu's PTAB
• Prop 65 Judge Out, Slams Bid's 'Aggressive' Privacy Invasion
• 1st Circ. Backs Convictions Of NECC Execs In Meningitis Case
• Tilray Gets Securities Fraud Claims Tossed For Now
• Zetia Buyers Renew Class Cert. Push After 4th Circ. Snag
• Romney, Kaine Press FDA On Delayed E-Cigarette Decisions
• McKesson Tells 9th Circ. Opioid FCA Suit Correctly Dropped
• Shkreli's Pharma Venture Loses Bid To Limit Profit Payback
• FTC Deepens Look At $1B Medtronic-Intersect Deal
• 8 Firms Guide 3 Cos. For $969M In Planned IPOs
• King & Spalding, O'Melveny Rep DL Unit's $2.5B Kraton Buy
• Insys Manager Asks Full 1st Circ. To Review 'Pill Mill' Guilt
• NJ Judge Refuses To Knock Down Rutgers Vax Requirement
• FlatWing Won't Get $690K Atty Fees In Pfizer Unit Patent Fight
• BASF, Cahill Gordon To Pay $22.5M Atty Fees In Asbestos Suit
• J&J Says Cyprus Can't Intervene In Imerys Coverage Fight
• NY Judge Won't Rush Ruling On City's Vaccine Mandate
• Embracing ESG: United Natural Foods GC Talks Bottom Line
• Theranos Execs Put PR Over Patients, Ex-Lab Chief Testifies
• Servicemembers Want Injunction Against DOD Vax Mandate
• Virginia Doctor Pleads Guilty In $1.8M Rx Fraud Scheme
• House Narrowly Approves Abortion Rights Bill
• Novo Nordisk To Pay $100M To Settle Investor Class Action
• COVID Test Maker, Analytics Firm Price IPOs Totaling $740M
• Arb. Clause Applies To MDs In Vaccine Suit, 3rd Circ. Told
• California AG Announces Appeal Of Purdue Ch. 11 Plan
• Miss. Lawmakers Reach Deal To Legalize, Tax Medical Pot
• What Plaintiffs Can Do If J&J Succeeds In Bankruptcy Strategy
• 3 Attorney Ethics Considerations For Litigation Funding
• Calif. Jury Awards $5M In Landmark Cannabis Antitrust Case
• Real Estate Rumors: Kolter Homes, Savanna, DR Horton
• Perkins Coie Snags Obama Vet For Offshore Wind Push
• 11th Circ. May Wait On High Court Ruling In Ga. Abortion Case
• Linda Evangelista Files $50M Suit Over 'Disfiguring' Procedure
• Monsanto PCBs Contaminated Del. Waterways, AG Suit Says
• Mich. Doctor Convicted In $100M Injections-For-Pills Scheme
• PTAB Upholds Bulk Of Claims In Medtronic Patents
• CytoDyn Investors Challenge Director Removal Rule In Del.
• MVP: Cohen Milstein's Sharon K. Robertson
• GE Healthcare Inks $1.45B Deal For Surgical Imaging Co.
• Insurer Wants 3M To Pay Up For Warming Device Defense
• Gov't Employees Sue Over Biden's COVID-19 Vax Mandates
• Chubb Slams Sweep Of Opioid Defense Order For Rite Aid
• Pot Researcher Urges 9th Circ. Redo Of Classification Appeal
• FDA Greenlights Pfizer Vaccine Boosters For COVID
• Aldi Freed From False-Ad Claims Over 'Vanilla' Almond Milk
• US Trustee Challenges Constitutionality Of Purdue Releases
• Watchdog Says DOD Drug Supply Chain At Risk For Upheaval
• Chancery Says Takeda Liable For AbbVie's Lupron Supply Lag
• How ABA Opinion Shifts Alternative Biz Structure Landscape
• Telehealth Providers Must Beware Of Fraud As Industry Grows
• Senate Panel Grills Biden's Pick For HHS Watchdog
• Pharma Giants' $454M Glumetza Antitrust Deal Gets Initial OK
• FCA Proposal Is Unfair And Would Hinder Economic Growth
• Mattis Doubted Theranos 'Transparency,' Holmes Jury Hears
• Plaintiff Fact Sheets In Mass Tort Discovery: Keys To Success
• MVP: Keker Van Nest's Laurie Mims
• Latham Hires Vinson Veteran For Energy M&A Practice
• United Airlines Faces Bias Suit Over COVID-19 Vax Mandate
• Pharmacies Win Remand Of FDA's Compounded Drug Memo
• Theranos Test Wrongly Suggested Miscarriage, Jury Hears
• Elysium Gets Dartmouth Vitamin B3 Patents Axed Under Alice
• 100s Of Attys Air Warring Views In High Court Abortion Fight
• Ohio Counties Want Unvaxxed Jurors Out Of Opioid MDL Trial
• PwC Can't Shed City's Claim In Valeant Securities Suit
• AbbVie Calls Retailers' Bystolic Generic Delay Claims Flawed
• Vaping Industry Rips Into FDA After Nearly 1M Products Pulled
• Attys Seek $610K In $1.8M Dollar General False Ad Settlement
• Blackstone Unit To Invest £850M In UK Lab Space
• Paragard IUD Maker Wants 'Shotgun' MDL Claims Tossed
• MVP: Skadden's Jennifer Bragg
• Sandoz Infringed Amgen's Psoriasis Drug Patents, Court Says
• J&J May Court Trouble With 'Texas Two-Step' Talc Gambit
• Barbados Co. Says $12M COVID Vaccine Deal Was A Scam
• Lupin Will Pay $150M To End Glumetza Antitrust Suit
• Imerys Ch. 11 Vote Change Challenged By Del. Judge
• Justices Set Abortion Fight Oral Arguments For Dec. 1
• Bausch Execs Escape Derivative Suit Over Fraud Scheme
• Pressure Mounts On USPTO To Join Drug Pricing Fight
• Hemp Equipment Co. Denies $45M Fraud Suit Implicates It
• Embracing ESG: HPE Counsel Talk Effective Board Oversight
• Illumina's Early Deal Close Draws EU 'Interim Measures'
• Judge Limits Stanford Doctor's Testimony In Opioid MDL
• No 'Bad Faith' To Justify Fee Award In Docs Suit, Biogen Says
• MVP: Gibson Dunn's Jane M. Love, Ph.D.
• Justices Told 2nd Circ. Ruling Puts Well-Known TMs At Risk
• Bankruptcy Courts' Equitable Discretion May Be In Danger
• Ropes & Gray-Led Lab Space Provider Lands $250M Series B
• Holmes Rushed Device Testing For Walgreens Deal, Jury Told
• Travelers Doesn't Owe Northrop Coverage In Pollution Suits
• Rosen Law Firm To Lead Investor Suit Against Botox Rival
• Endo's Attys In 'Career-Wrecking' Peril As Opioid Woes Grow
• Ex-Mylan Info Tech VP Cops to $8M Insider Trading Scheme
• Family of Pilot Killed Fighting Wildfire Sues Helicopter Maker
• Myriad Board Under Fire For Allegedly Overselling Gene Test
• Insurer Asks 9th Circ. To Affirm Opioid Coverage Dispute Win
• Fed. Circ. Upholds ITC Infringement Finding On Milk Patent
• 3rd Circ. Preview: Antitrust, Defamation Suits Kick Off Fall
• DePuy Escapes Implant Suit After Expert Is Limited
• AI Inventorship Decision Leaves Open Questions
• Pot Grower Says Careless Cigarette Toss Caused $40M Fire
• Polish Pharma Co. Gets Arbitration Bid OK'd In IP Fight
• Justice Gap Demands Look At New Legal Service Models
• 3 Firms Win $1.3M In Fees From Zynerba CBD Gel Settlement
• Health Hires: Holland & Knight, Arnall Golden Gregory
• FDA Panel Backs Pfizer COVID Booster For Some Groups
• Judge OKs $2M Preliminary Deal in Indivior Stock Drop Suit
• MVP: Ropes & Gray's Hannah H. England (Freeman)
• DOJ Targets Telemedicine Fraud In $1.4B Enforcement Action
• JSR Pays $514M For Inpria To Strengthen Semiconductor Biz
• UK Litigation Roundup: Here's What You Missed In London
• Cybercrime Spree Raises Risks Of Insurance Coverage Battles
• Grifols Grabs German Plasma Co. At €2B Enterprise Value
• Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself
• Ohio Cuts $808M Opioid Distributor Deal Plus $42M Legal Fee
• Vitamin C Cos. Want Third Shot At 2nd Circ. In Price-Fix Case
• IP Forecast: Trial Lawyer School TM Fight Lands At 10th Circ.
• Trulieve Seeks Exit From Noncompete Row Over Exec Hiring
• Galena Settles Investors' Revived Opioid Row For $1.6M
• Imerys Tort Claimants Want To Change Ch. 11 Vote To 'Yes'
• Patient Says Removal Of Ethicon Mesh Didn't Tip Her To Injury
• Deals Rumor Mill: Stripe, Novolex, Unilever
• Skadden, Kirkland Lead Prenetics' $1.7B SPAC Deal
• Philip Morris' £1.1B Vectura Buy On Track Despite Objections
• Apple Wants Fed. Circ. To Rethink Refusal To Toss Patent Suit
• Becton Beats FDA Approval Claims In Securities Suit
• Pa. AG Says DAs Can't Sue To Stop $26B Opioid Settlement
• Judge Erred By Nixing $3M From Verdict, 1st Circ. Finds
• US Trustee To Appeal Sackler Releases In Purdue Ch. 11
• David Boies Threatened Theranos Whistleblower, Jury Told
• 9 Companies Storm Capital Markets With IPOs Totaling $3B
• Impax Wants High Court To Undo 5th Circ. Loss To FTC
• Allergan Cuts Deal With Generic Cos. Over Depression Drug
• 4 Firms Seek To Lead Biotech Stock Promotion Scheme Suit
• How SPAC Investors Might Rethink Material Adverse Effect
• Ivantis To Pay $60M To End Patent Fight Over Glaucoma Tech
• FDA Biosimilar Approval Foreshadows IP Litigation Issues
• Willkie Farr Exec Says Attys Have Shown They Can Be Remote
• Court Won't Rush Feds' Decision On Protecting Ancient Fish
• Pa. Justices Won't Review Housing Rules For Medical Pot
• Omnicare To Pay $1M To Settle Drivers' Misclassification Suit
• Goodwin Nabs Dechert IP Partner For Life Sciences Team
• Holmes Fan's #MeToo Callout To Jurors Draws Judge's Ire
• Biden Admin. Hit With 1st State AG Suit Over Vax Mandate
• CDC, FDA Issue Warnings About Delta-8 THC 'Weed Light'
• Apotex, Mylan Urge Full Fed. Circ. To Ax Cancer Drug Patent
• Fla. Biotech Co.'s Misleading IPO Hurt Investors, Suit Says
• USCIS To Require Full COVID-19 Vaccination To Immigrate
• 'Red Flag' Expert's Opinion Limited In Opioid MDL
• Mallinckrodt Aims To Push Back Ch. 11 Plan Hearing Until Oct.
• Generics Group, Intel Back Mylan's Fintiv Fight At High Court
• Zydus, Takeda Tell 3rd Circ. Antitrust Appeal In Right Place
• Fed. Circ. Told Inventor Limits Don't Bar Validity Challenge
• Rutgers Students Can't Remove Judge In COVID Vaccine Suit
• After Gerber HQ Mix-Up, Judge Moves Baby Food Case To Va.
• These Firms Have The Most Women In Equity Partnerships
• Greenberg Traurig Taps Ex-FDA Atty For Litigation Team
• 2nd Circ. Vitamin C Price-Fixing Decree Goes Beyond Antitrust
• High Court's Legitimacy Tested In Abortion Row, Justices Told
• FDA Wants To Team Up With USPTO Over Drug Pricing
• FDA Asks Full DC Circ. To Consider Electric Shock Device Ban
• Pot Growers Say Calif. Cops Ran Extortion Ring In RICO Suit
• AbbVie Escapes Shareholder Suit Over Failed Shire Merger
• Cyprus Mines Asks To Join Imerys Ch. 11 J&J Suit
• Mallinckrodt Creditors Say Ch. 11 Plan Understates Revenues
• Balwani's Counsel Can't Reserve Seats To Watch Holmes Trial
• Embracing ESG: Leidos GC Talks Social Responsibility
• Purdue Pharma Gets OK For $7.1M In Exec Incentives
• J&J Says Plaintiff Firms Can't Hide From Talc Media Subpoena
• Dual MD, JD Partner Joins Foley Hoag In DC
• Retina Drug Co. Settles Investor Row For $29M
• Law360's Glass Ceiling Report: What You Need To Know
• Pharma Cos. Should Prepare For New Drug-Rebate Scrutiny
• J&J Targeted Overweight Women For Talc Sales, Jury Hears
• Oklahoma Pot Grower Says It Was Caught In Law Firm's Scam
• UK Watchdog Fears 'Race To Bottom' On COVID Testing
• Teva Loses Bid To Dodge Most Of Feds' FCA Case
• What's At Stake In High Court's CVS Disability Bias Case
• Haynes And Boone Launches CBD, Hemp Industry Practice
• 15 Firms To Guide IPOs Exceeding $3.4B As Activity Resumes
• CBP Removes Top Glove From Forced Labor Blacklist
• J&J Courted 'Death And Destruction' With Talc, Jury Hears
• Endo Strikes $50M Opioid Deal In NY Amid Trial Tumult
• HHS Targets Drug Prices In New Proposal
• Elizabeth Holmes' Fraud Trial Delayed Over Virus Concerns
• Allergan Investor Class Certified With New Lead Plaintiff
• Jury Hands CR Bard A Win In Ohio Hernia Mesh Bellwether
• 11th Circ. Nixes Emory Doctor's Race Bias Suit
• Pharma Giants Ink $300M Deal To End Glumetza Antitrust Suit
• Pacific Legal Backs Challenge To Drug Program Cuts
• Shkreli Antitrust Trial Slated For Mid-December
• Sierra Club, Others Say EPA Must Close Emissions Loopholes
• FDA Delays On Juul, Orders Other E-Cigs Off Market
• Unvaccinated Aegerion Rep Can't Delay Prison, Feds Say
• 9th Circ. Backs Class Cert. In Theranos Blood Test Suit
• Lessons In Crisis Lawyering 20 Years After 9/11
• Mylan Pushes Back Against EpiPen Buyers' Appeal Bid
• Opioid MDL's Tribal Bellwether Paused, Global Deal Possible
• Nonprofit Sues FDA Over Unanswered Hair Loss Drug Petition
• Ga. Sterilizer Says Alleged Cancer-Causing Emissions Legal
• Insurers Beat Benecard's 3rd Circ. Fraud Suit Coverage Fight
• Biz Groups Ask Harris To Push Mexico To Enforce Trade Deal
• Student Vaccine Mandate Considerations For Private Schools
• Mallinckrodt Pushes Back Ch. 11 Plan Vote After $583M Deal
• Bid Protest Spotlight: Informalities, Reevaluation, Ethics
• Neb. Medical Pot Legalization Activists Eye 2022 Do-Over
• Ill. Judge Gives Final OK To $800K Deal Over Drug Faxes
• CPAP Maker Sued Over Recall For Chemical Inhalation Risk
• PTAB Wipes Out BASF Patent On Fatty Acid
• Patent Owner Estoppel Isn't As Threatening As It Seems
• AbbVie Loses Chancery Fight For Takeda Contract Injunction
• Insurer Should Defend Opioid Suits, Ohio Court Told
• Holmes' Fraud Trial Openings Draw Crowds, Look-Alikes
• Trulieve Settles Hiring Class Action After Cert.
• 4 Firms Craft Perrigo's $2.1B Deal For PE-Owned Self-Care Co.
• From Boies To Mattis, Theranos Trial Promises VIP Witnesses
• CVS Tells High Court Mailed Prescriptions Not Disability Bias
• Ex-Pharma HR Head Aims To Revive Japanese Favoritism Suit
• Chicago's Discovery Bid A Defective 'Attack,' Endo Says
• US Report Shows Pandemic's Toll On International Trade
• The Regulatory Growing Pains For Digital Health Companies
• SpineFrontier Execs Hit With Charges In Kickback Scheme
• Mich. Sens. Aim To Ax Morality Clause From Medical Pot Law
• AbbVie Settles Patent Dispute Over Muscle Stimulation Tech
• Lead Counsel Battle Heats Up In $1.8B Biotech Sale Suit
• Court Says Counterclaims In Pot Software Row Can Proceed
• Rutgers Students Seek To Oust Judge In COVID Vaccine Suit
• SEC Says Mallinckrodt Ch. 11 Plan Releases Should Be Opt-In
• Ark. Suit Against Pot Law Firm May Require Arbitration In NY
• Fed. Circ. Affirms Bristol-Myers, Pfizer Win In Eliquis IP Row
• Purdue's 'Bitter' Pill For Victim Recoveries Here To Stay
• Bard Denied Early Win In Hernia Mesh Bellwether
• No Excuse To Delay Discovery, Mallinckrodt Claimants Say
• Snell & Wilmer Adds IP Pro To Growing San Diego Office
• Teva Drops Claim That Rival Slowed Generic Development
• Epstein Becker Opens Ohio Office With 12-Partner Group
• IP Forecast: Herman Miller Readies For Chair TM Fight
• Chickasaw Want Arbitration Order Tossed In Rx Payback Suit
• DEA Letter On Psychedelics Is Agency Action, 9th Circ. Hears
• The Latest Fed. Circ. Antibody Rulings You Need To Know
• Alexion Must Face Claims Of Stalling On Drug After Merger
• Pharma Co. Beats Shareholder Suit Over Migraine Drug
• Celgene Can't 'Guess' How Rival Mylan Operates, Judge Says
• Calif. Jury Empaneled In Trial Of Ex-Theranos CEO Holmes
• Northern Calif. County Dismissed From Pot Farm Raid Suit
• DC Circ. FCA Ruling Raises Bar For Alternate Remedies
• Lab Maker Says Ex-Exec Stole 10,000 Docs For New Employer
• Swedish Drug Co. Backs $8B Buyout Offer From Advent, GIC
• Why Structured Data Is Increasingly Important To Your Case
• Sullivan & Cromwell, Wachtell Rep $12.4B Deal For Hill-Rom
• Holmes Trial Jury Pool Narrowed For Final Day Of Selection
• 3 Firms Vie To Lead Stock Drop Suit Over Vax Candidate
• Another Federal Judge Tosses An Investor Suit Over Diversity
• Pot Giants Ayr, Planet 13 Ink Deals Worth $135M Combined
• Ex-Drug Distributor CEO Slated For January Opioid Trial
• Endo Beats Investors' Opioid Crisis Class Suit, For Now
• Law Firms Aim To Sink J&J Subpoenas For Talc Media Info
• Chancery Throws Out Challenge To $5.1B Tesaro Sale
• Eli Lilly Favors Millennial Applicants, Older Job Seekers Say
• Walmart Is Latest Co. Hit With Baby Food Heavy Metal Suit
• Surgical Implant Co. Settles Securities Suit For $10.5M
• Indivior's Suboxone Patent Fight Faces Wary Fed. Circ.
• Embracing ESG: AIG Counsel Talks SEC Risk Alert
• Procter & Gamble Slips 'Natural' Pantene Shampoo Label Suit
• Purdue Pharma Ch. 11 Plan Gets OK With Sackler Releases
• Fed. Circ. Teva Ruling May Shake Up Skinny Label Strategies
• Latham Opens Austin Office With Focus On Emerging Cos.
• Belcher's Withheld Prior Art Again Dooms Drug Patent Suit
• PE Firm AGIC Capital Clinches $1.2B For 2nd Fund